NEW YORK, NY / ACCESSWIRE / August 11, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
TGTX Shareholders Click Here: https://www.zlk.com/pslra-1/tg-therapeutics-loss-submission-form?prid=30790&wire=1
YQ Shareholders Click Here: https://www.zlk.com/pslra-1/17edtech-loss-submission-form?prid=30790&wire=1
KRBP Shareholders Click Here: https://www.zlk.com/pslra-1/kiromic-lawsuit-submission-form?prid=30790&wire=1
* ADDITIONAL INFORMATION BELOW *
TG Therapeutics, Inc. (NASDAQ:TGTX)
TGTX Lawsuit on behalf of: investors who purchased January 15, 2020 - May 31, 2022
Lead Plaintiff Deadline : September 16, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/tg-therapeutics-loss-submission-form?prid=30790&wire=1
According to the filed complaint, during the class period, TG Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company's therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib's clinical and/or commercial prospects; and (iv) therefore, the Company's public statements were materially false and misleading at all relevant times.
17 Education & Technology Group Inc. (NASDAQ:YQ)
This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded 17EdTech securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with 17EdTech's December 2020 initial public offering.
Lead Plaintiff Deadline : September 19, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/17edtech-loss-submission-form?prid=30790&wire=1
According to the filed complaint, (1) 17EdTech's K-12 Academic AST Services would end less than a year after the Company's initial public offering; (2) as part of its ongoing regulatory efforts, Chinese authorities would imminently curtail and/or end 17EdTech's core business; and (3) as a result, defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Kiromic BioPharma, Inc. (NASDAQ:KRBP)
This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Kiromic common stock issued in connection with the Company's public offering that closed on July 2, 2021 and/or (b) Kiromic common stock between June 25, 2021 and August 13, 2021, both dates inclusive.
Lead Plaintiff Deadline : October 4, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/kiromic-lawsuit-submission-form?prid=30790&wire=1
The complaint alleges that the registration statement and prospectus issued in connection with the Company's public offering that closed on July 2, 2021 (the 'Offering Documents') failed to disclose that the Food and Drug Administration ('FDA') had, prior to the filing of these documents, imposed a clinical hold on the Company's Investigational New Drug ('IND') applications for its two new drug candidates. Given that the offering closed on July 2, 2021, more than thirty (30) days after the Company submitted the IND applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE : Levi & Korsinsky, LLP
View source version on accesswire.com: